Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Peginterferon-alpha(2b) and ribavirin.

Joseph Ahn1, Steven Flamm

  • 1Department of Medicine, Northwestern University Medical School, Northwestern Memorial Hospital, Chicago, IL 60611, USA.

Expert Review of Anti-Infective Therapy
|October 16, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Top-down control and species composition influence nonlinearly the short-term response of experimental food webs to a nutrient pulse perturbation.

Proceedings. Biological sciences·2026
Same author

Alcohol-Related Liver Disease: Novel Insights into Mechanism.

Clinics in liver disease·2025
Same author

AGA Clinical Practice Update on Management of Hepatitis Delta: Commentary.

Gastroenterology·2025
Same author

Targeting Hsp70 Immunosuppressive Signaling Axis with Lipid Nanovesicles: A Novel Approach to Treat Pancreatic Cancer.

Cancers·2025
Same author

Scaffold implantation <i>vs.</i> intravenous delivery: a comparative preclinical animal study evaluating peroxisome proliferator-activated receptor gamma coactivator 1-alpha adipose-derived stem cells in liver fibrosis treatment.

Annals of surgical treatment and research·2025
Same author

Larsucosterol for the Treatment of Alcohol-Associated Hepatitis.

NEJM evidence·2025

Pegylated interferon-alpha(2b) combined with ribavirin offers improved efficacy for treating chronic hepatitis C virus infection compared to standard interferon. This combination therapy demonstrates safety and ease of use for patients.

Area of Science:

  • Hepatology
  • Virology
  • Pharmacology

Background:

  • Hepatitis C virus (HCV) infection is a leading cause of chronic liver disease globally, affecting 300 million people.
  • HCV is the primary indication for liver transplantation in the USA, with projected growth in cases.
  • Previous treatments like interferon-alpha(2b) monotherapy and combination therapy showed limited success.

Purpose of the Study:

  • To review data on pegylated interferon-alpha(2b) (Peg-intron) with ribavirin therapy for chronic hepatitis C virus infection.
  • To present pharmacokinetics, pharmacodynamics, and clinical trial data for this combination therapy.

Main Methods:

  • Review of clinical trial data on pegylated interferon-alpha(2b) and ribavirin combination therapy.
  • Analysis of pharmacokinetic and pharmacodynamic properties of the combined treatment.

Related Experiment Videos

Main Results:

  • Pegylated interferon combination therapy demonstrated improved efficacy over standard interferon combination therapy.
  • The combination therapy did not show an increase in adverse effects compared to standard treatments.
  • The efficacy and ease of use of Pegintron and ribavirin support their application.

Conclusions:

  • Pegylated interferon-alpha(2b) with ribavirin is an effective treatment for chronic hepatitis C virus infection.
  • This combination therapy represents a significant advancement in HCV treatment.
  • The safety and efficacy profile supports its widespread use in managing chronic hepatitis C.